Demant CEO: Prognosis held back by uncertainty about momentum's duration
Demant’s first-quarter success was partially due to the launch of flagship product Oticon Real, which created particular interest among hearing aid users.
by marketwire, translated by christian radich hoffman
Hearing aid manufacturer Demant’s upwards adjustment of its 2023 prognosis in mid-April is mainly steered by the strong development during the year’s first quarter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
